Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,166 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
Miami, FloridaAges 18 years+ - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT04892849Recruiting
PD-1/PD-L1 immunotherapy plus radiation for solid tumors
This study tests whether combining an immune system medicine (PD-1/PD-L1 inhibitor) with radiation can improve outcomes in people with certain solid cancers. It also looks for blood or tissue “biomarkers” that may explain who benefits most.
Erlangen, BavariaAges 18 years+ - NCT04975152RecruitingPhase 1
Cemiplimab before surgery for Merkel cell and skin cancers
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
Tampa, FloridaAges 18 years+ - NCT04981509RecruitingPhase 2
Check if 3 medicines help advanced kidney cancer
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
La Jolla, CaliforniaAges 12 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05098119RecruitingPhase 2
Study drugs before surgery for mouth or throat cancer
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
Guangzhou, GuangdongAges 18–80 - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT05726370RecruitingPhase 2
Pembrolizumab plus chemo before surgery for recurrent head and neck cancer
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
Boston, MassachusettsAges 18 years+ - NCT05747625RecruitingPhase 1
PET/CT scan using panitumumab to find head and neck cancer spread
This Phase 1 study tests a new way to use a scan (PET/CT) with a drug called panitumumab to help spot where head and neck squamous cell cancer has spread. It may help doctors better target treatment by finding metastases earlier or more clearly.
Nashville, TennesseeAges 19 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05952947RecruitingPhase 1
Study drug for HPV18-positive solid tumors with a specific immune marker
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05955924RecruitingPhase 3
Nicotinamide to prevent skin cancer after organ transplant
This trial tests nicotinamide (a vitamin-like medicine) to help prevent new keratinocyte skin cancers in people who have had a kidney, liver, heart, or lung transplant. It may lower the chance of developing new skin tumors while you continue your usual transplant anti-rejection medicines.
Calgary, AlbertaAges 18 years+ - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Fort Smith, ArkansasAges 18 years+ - NCT06118086RecruitingPhase 1/Phase 2
Study of REM-422 for advanced adenoid cystic carcinoma
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06161545RecruitingPhase 2
Immunotherapy before surgery for head and neck cancer
This trial tests whether giving a combination of immunotherapy drugs (pembrolizumab, N-803, and possibly PD-L1 t-haNK cells) before surgery can help treat head and neck cancer that has not been treated yet. It is for people whose cancer is p16-negative (a specific marker) and is at an intermediate or high risk of coming back.
Bethesda, MarylandAges 18–120 - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+ - NCT06295965Recruiting
Blood changes and cancer therapy study
This study looks at why some people develop blood disorders after cancer treatment. It monitors changes in blood cells to better predict and prevent these problems.
Seattle, WashingtonAges Any age - NCT06302569RecruitingPhase 2
Pembrolizumab plus enfortumab vedotin for rare kidney cancers
This trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and enfortumab vedotin (a targeted therapy)—for people with collecting duct carcinoma or renal medullary carcinoma, two rare types of kidney cancer that have spread. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
MilanAges 18 years+ - NCT06321484RecruitingPhase 1
NK cell therapy for recurrent platinum-resistant ovarian cancer
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
Boston, MassachusettsAges 18–85 - NCT06440850RecruitingPhase 2
Targeted therapy for high-risk BRAF-mutated thyroid cancer
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Duarte, CaliforniaAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Tucson, ArizonaAges 18 years+ - NCT06682442Recruiting
Chemotherapy-guided radiation for EBV-related nasopharyngeal cancer
This trial tests whether the response to initial chemotherapy can guide the dose of radiation given to patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. The goal is to tailor treatment to reduce side effects while still being effective.
San Francisco, CaliforniaAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,166 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.